Enrolling By InvitationNCT07459660
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
Medication studyAges 55–91Multiple countriesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 55 years to 91 years.
- Listed locations
- Anaheim and 7 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 25, 2026
- Recruitment status
- Enrolling By Invitation
- Enrollment listed in the registry
- 210
- Sponsor
- MapLight Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, France, Bulgaria
- Age range
- From 55 Years to 91 Years
- Official registry ID
- NCT07459660
- Official title
Show the full official title
An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML007C-MA in Adult Participants With Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
Recruitment & locations
By invitationThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Anaheim, United States · Doral, United States · Miami, United States
4 more locations
- Miami Gardens, United States
- Orlando, United States
- Pernik, Bulgaria
- Toulouse, France
Questions about this study
Who is behind this study?
The study sponsor is MapLight Therapeutics.
Does this study involve medication?
Yes. The study involves medication, including ML-007C-MA.
Who can participate?
Listed age limits: 55 years to 91 years.
Is this study still recruiting?
The registry lists this study as enrolling by invitation.
